
Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017

Mai-Juan Ma,¹ Cheng Liu,¹ Meng-Na Wu, Teng Zhao, Guo-Lin Wang, Yang Yang, Hong-Jing Gu, Peng-Wei Cui, Yuan-Yuan Pang, Ya-Yun Tan, Hui Hang, Bao Lin, Jiang-Chun Qin, Li-Qun Fang, Wu-Chun Cao, Li-Ling Chen

Avian influenza A(H7N9) virus has caused 5 epidemic waves in China since its emergence in 2013. We investigated the dynamic changes of antibody response to this virus over 1 year postinfection in 25 patients in Suzhou City, Jiangsu Province, China, who had laboratory-confirmed infections during the fifth epidemic wave, October 1, 2016–February 14, 2017. Most survivors had relatively robust antibody responses that decreased but remained detectable at 1 year. Antibody response was variable; several survivors had low or undetectable antibody titers. Hemagglutination inhibition titer was $\geq 1:40$ for <40% of the survivors. Measured *in vitro* in infected mice, hemagglutination inhibition titer predicted serum protective ability. Our findings provide a helpful serologic guideline for identifying subclinical infections and for developing effective vaccines and therapeutics to counter H7N9 virus infections.

The novel avian influenza A(H7N9) virus has caused 5 epidemic waves in China since its emergence in 2013. As of September 20, 2017, a total of 1,561 human cases were reported, with a case fatality rate of $\approx 39\%$ (1). In particular, a substantial increase of 758 human cases was reported during the fifth epidemic, compared with the earlier 4 (1). Highly pathogenic H7N9 viruses emerged and infected both humans (1) and poultry (2) during the fifth epidemic. In addition, H7N9 virus readily obtained the 627K or 701N mutation in its polymerase basic (PB) 2 segment upon replication in ferrets (3), suggesting that the virus has pandemic potential and continues to pose grave risks to public health.

The H7N9 subtype has the highest risk score among the 12 novel influenza A viruses evaluated by the Centers

for Disease Control and Prevention using the Influenza Risk Assessment Tool and is characterized as posing moderate-to high-potential pandemic risk (4). Apart from the ongoing monitoring of virologic and molecular characteristics of H7N9 viruses in poultry and humans, studies on the dynamic changes of antibody response in survivors are critical for serologic diagnosis, population-based seroepidemiologic surveys, and vaccine design and development. A few studies have investigated virus-specific antibody kinetics to the H7N9 virus in patients and their relationship with disease severity (5–7), but these studies were restricted to antibodies measured in the acute and convalescent phases. No follow-up studies have been done on dynamic antibody changes in survivors who had recovered from the disease. As a result, the long-term serologic response to H7N9 virus infections is poorly understood and remains of clinical interest. In our study, we investigated the long-term dynamic changes in antibody response in H7N9 survivors identified during the fifth epidemic in China and examined the relationship between antibody responses and clinical characteristics.

Materials and Methods

Study Design and Participants

During the fifth epidemic wave of the H7N9 virus (October 1, 2016–February 14, 2017), we conducted a longitudinal serologic survey on a cohort patient who had recovered from the disease in Suzhou, Jiangsu Province, China. We screened 34 patients who had laboratory-confirmed cases and were >18 years of age when they were discharged from the hospital (Figure 1). We enrolled 25 of these patients in our study after obtaining informed consent and prospectively followed them at ≈ 100 , 200, and 300 days after symptom onset (Figure 1). In addition, we enrolled 10 control subjects who live in an area without known H7N9 virus detections, denied close contact with live poultry or live bird markets during the previous 12 months, and had no known diseases or conditions that would reduce their immune response.

Author affiliations: Beijing Institute of Microbiology and Epidemiology, Beijing, China (M.-J. Ma, M.-N. Wu, T. Zhao, G.-L. Wang, H.-J. Gu, L.-Q. Fang, W.-C. Cao); University of Florida, Gainesville, Florida, USA (Y. Yang); Suzhou Municipal Center for Disease Control and Prevention, Suzhou, China (C. Liu, P.-W. Cui, Y.-Y. Pang, Y.-Y. Tan, H. Hang, B. Lin, J.-C. Qin, L.-L. Chen)

DOI: <https://doi.org/10.3201/eid2404.171995>

¹These authors contributed equally to this article.




Figure 1. Schematic outline for study of influenza A(H7N9) virus antibody responses in survivors 1 year after infection, China, 2017. IQR, interquartile range.

We obtained written informed consent from all participants before conducting interviews and sample collection. The study protocol was approved by the Institutional Review Boards of Beijing Institute of Microbiology and Epidemiology and Suzhou Municipal Center for Disease Control and Prevention. The study was also approved by the Animal Care and Use Committee at the Academy of Military Medical Sciences.

Sampling and Data Collection

At patient enrollment, we used a comprehensive questionnaire to collect information about patients' demographic and clinical characteristics, history of exposure to poultry, and history of seasonal influenza vaccination. We included archived acute- or convalescent-phase serum samples from the participants in our study. At each of the 3 follow-up visits, we asked each participant to provide a 5-mL blood sample. We used a shorter questionnaire to collect information about demographic characteristics, recent history of exposure to poultry, and experience of influenza-like illness.

Serologic Testing

We measured serum hemagglutination inhibition (HI) antibody (8) by the HI assay; neutralizing antibody by

the microneutralization (MN) assay (9); neuraminidase inhibition (NI) antibody by the enzyme-linked lectin assay (ELLA) (10); and IgG or IgA antibodies by ELISA (5). For HI, NI, and MN detection, we applied 2-fold serial dilutions of serum from 1:10 to 1:280. We defined the HI titer as the reciprocal of the highest serum dilution that completely inhibited hemagglutination; the NI titer as the reciprocal of highest serum dilution that exhibited 50% inhibition concentration (IC_{50}); and the MN titer as the reciprocal of the highest serum dilution that yielded $\geq 50\%$ neutralization. For final titers $< 1:10$ we assigned a value of 1:5 (seronegative). For IgG and IgA detection, we tested serum samples at a starting dilution of 1:50 with 2-fold serial dilutions to 1:12,800. The endpoint titer was the highest dilution giving an optical density at least twice that of background. The final titers $< 1:50$ we assigned a value of 1:25. We used a human H7N9 isolate (A/Jiangsu/Wuxi05/2013) for the HI and MN assays. We used a genetic reassortant H6N9 virus, which contains the hemagglutinin gene of H6N1 virus A/Taiwan/1/2013, the neuraminidase gene of H7N9 virus A/Anhui/1/2013, and other internal genes of A/Puerto Rico/8/1934 H1N1, for ELLA. We used currently circulating human seasonal viruses (A/Shanghai/SWL1970/2015/H1N1 and A/Switzerland/

9715293/2013/H3N2) to examine the serum samples for cross-reacting antibodies with HI assay.

We defined a seroprotective threshold as an HI, NI, or MN antibody titer of 40. A titer of $\geq 1:40$ of HI, NI, or MN antibody has been shown to protect against seasonal influenza viruses (11–13) and is considered protective against H7N9 infection in humans, but has not been proven so. There is no established correlation of protection for IgG and IgA titers for influenza virus infection, but any detectable antibody level is deemed protective. We set the cutoff value for IgG titer to 1:400 because the mean titer among control serum samples was 1:350.

Human Serum Passive Transfer and H7N9 Infection of Mice

We obtained 42 female 4-week-old specific pathogen-free BALB/c mice from the Laboratory Animal Center, Academy of Military Medical Sciences, Beijing, China. The mice weighed 13.3 ± 0.9 g. We injected 3 mice per group intravenously with 40 μ L of human serum (2-fold serial HI titration ranged from 1:5 to 1:1,280) 12 hours before injecting them intranasally with 20 μ L of $10 \times 50\%$ lethal dose of H7N9 virus. We gave an equal volume of healthy donor serum or phosphate-buffered saline to control mice. We observed the mice daily for signs of disease for ≤ 3 days. We conducted all work with the H7N9 virus in the Biosafety Level 3 laboratory of the State Key Laboratory of Pathogen and Biosecurity.

Antibody in Serum and Virus Titers in Lungs of Mice

We collected blood from the mice 12 hours after injection with human serum. Because we transferred only 40 μ L serum to the mice and there was ≈ 30 -fold dilution of >1 mL blood, we expected the HI titer in mice to be undetectable. Therefore, we used the ELISA method to measure IgG titers. To obtain virus titers, we harvested the lungs of 3 mice at 3 days after virus infection and homogenized them into 1.5 mL of Dulbecco's Modified Eagle Medium using a manual homogenizer. We aliquoted lung homogenates and kept them at -80°C . We determined the viral titer using the tissue culture infectious dosage on MDCK cells.

Statistical Analysis

We analyzed the antibody titers with \log_{10} -transformed geometric means and 95% CIs. We calculated the proportion of antibody titers equal to or greater than seroprotective threshold (HI, NI, and MN) or limit of detection and associated 95% CI. We used Mann-Whitney U test for testing the differences in antibody titers and χ^2 test and Fisher exact test for testing the differences in proportion of antibody titers above thresholds. All statistical tests were 2-sided with a significance level of 0.05. We conducted all statistical analyses using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA).

Results

During October 1, 2016–February 14, 2017, we enrolled in our study 25 laboratory-confirmed H7N9 survivors from Suzhou, Jiangsu Province, China (Figure 1). Among these survivors, 17 were men and 8 were women; the median age was 59 years (range 49.5–66.5 years) (Table 1). All patients required hospitalization at 1–12 days after symptom onset. Most of the patients had severe illness and were admitted to the intensive care unit (ICU). Patients remained in the ICU for 7–30 days. Clinical symptoms included fever, cough, sore throat, fatigue, myalgia, chills, and dyspnea (Table 2). All patients received oseltamivir, and 21 received glucocorticoid for treatment. Laboratory tests at hospital admission showed that some patients had abnormal hepatic function. Most patients had low to medium viral load (online Technical Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/24/4/17-1995-Techapp1.pdf>). In addition, H7N9 viruses isolated from 11/25 patients were of low pathogenicity and belonged to the Yangtze River Delta hemagglutinin lineages (online Technical Appendix Table 1). The radiographic findings included pneumonia, increased markings, fuzzy patch lesions, and patch effusion shadows in lungs (online Technical Appendix Table 2).

Table 3 shows the proportion of survivors with antibody titers equal to or greater than the seroprotective threshold (1:40 for HI, NI, and MN) or the minimum detection limit (1:400 for IgG and 1:50 for IgA) at each time point. Counting from the day of symptom onset, $>90\%$ of survivors had an HI titer $\geq 1:40$ on day 100. This proportion reached 82.6% on day 200 but decreased to 36.4% on day 300. The overall patterns of the NI antibody titers were similar to the HI antibody titers, except that 63.6% of survivors had an NI titer $\geq 1:40$ on day 300. Unlike the HI and NI antibody titers, the proportion of seroprotective MN ($\approx 86\%$) and IgG (100%) titers remained steady over time. For IgA antibody titers, the seroprotective proportion decreased from 96% on day 100 to $\approx 60\%$ on day 300, an absolute reduction of $\geq 30\%$.

The geometric mean titers (GMTs) of antibodies were plotted by the time points in Figure 2. Overall, ≈ 300 days after symptom onset, HI and NI GMTs substantially declined and were lower than the seroprotective threshold of 1:40 and the GMTs in the acute phase (Figure 2, panels A and B). In contrast, the MN GMTs increased over time, peaked on day 200, and then declined by day 300, yet remained considerably above the GMTs in the acute phase and the seroprotective threshold of 1:40 (Figure 2, panel C). Although we observed no substantial difference in GMTs across 3 follow-up time points, the MN GMTs on day 200 were relatively high, suggesting a possible delayed response after infection. IgG and IgA decreased gradually from day 100 to day 300 but remained higher than the limit of detection (Figure 2, panel D). However, IgG GMTs on

Table 1. Clinical characteristics of influenza A(H7N9) virus survivors, China, 2017*

Patient no.	Age, y/sex	Symptoms	Days to admission†	Hospitalization, d	ICU, d	Disease severity
1	89/M	Fever, cough, sore throat, fatigue, myalgia	6	18	16	Severe
2	32/M	Fever, cough, sore throat	12	22	12	Severe
3	41/F	Fever, cough, sore throat, fatigue	8	19	14	Severe
4	83/M	Fever, cough, fatigue	4	11	9	Severe
5	62/M	Fever, cough	7	12	12	Severe
6	71/M	Fever, cough	9	18	13	Severe
7	63/F	Fever, cough, fatigue	9	16	10	Severe
8	54/F	Fever, cough, sore throat	7	14	9	Severe
9	54/F	Fever, cough, fatigue	7	17	17	Mild
10	60/F	Fever, cough, fatigue, chills	7	28	23	Severe
11	28/F	Fever, cough, fatigue	7	16	11	Severe
12	63/M	Fever, cough	6	14	14	Severe
13	65/M	Fever, cough	5	19	0	Severe
14	35/M	Fever, cough, sore throat, fatigue	6	12	12	Severe
15	39/F	Fever, cough	7	19	19	Severe
16	57/M	Fever, cough	10	17	17	Severe
17	75/M	Fever, cough, fatigue	9	22	13	Severe
18	58/M	Fever, cough, myalgia	5	15	8	Mild
19	54/F	Fever, fatigue, myalgia	5	11	11	Severe
20	59/M	Fever, cough	5	21	7	Severe
21	68/M	Fever, cough, dyspnea	5	30	30	Severe
22	59/M	Fever, cough	7	22	22	Severe
23	45/M	Fever, cough	1	13	9	Severe
24	71/M	Fever, cough	2	73	NA	Severe
25	64/M	Fever, cough, sore throat	6	13	11	Mild

*ICU, intensive care unit; NA, not available.

†After symptom onset.

day 200 and day 300 were substantially higher than the IgG GMTs in the acute phase, whereas the IgA GMTs on day 200 and day 300 were similar to those in the acute phase. There were no detectable antibodies to the H7N9 virus in the control subjects, but GMT was 283.3 (titer ranged from 1:200 to 1:800) for IgG, suggesting a possible cross-reactivity between the H7N9 virus and other subtypes.

Approximately 300 days after symptom onset, nearly all survivors had a ≥ 4 -fold decline in the HI titer compared with the titer on day 100, and 14 survivors had HI titers $< 1:40$ (Tables 4, 5; Figure 2, panel A). Among these 14 survivors, 2 (patients 1 and 2) maintained low titers (1:10) throughout the study period, but 2 others (patients 4 and 25) had undetectable titers around day 300. The other 10 survivors had titers of 1:20. Twenty-one survivors had a ≥ 4 -fold decrease of the NI titer ≈ 300 days after symptom onset, and 8 survivors (patients 1, 2, 4, 8, 11, 14, 22, and 25) had titers $< 1:40$ (Tables 4, 5). Among these 8 survivors, the titer of patient 2 declined to seronegative on day 349, and others had titers $\leq 1:20$ (Tables 4, 5; Figure 2, panel B). In contrast, the majority of survivors had a ≥ 2 -fold increase in MN titer (9 survivors) or maintained MN titer (8 survivors) on day 200 in comparison to day 100 after symptom onset, followed by a decrease or a maintenance on day 300 (Figure 2, panel C; Tables 4 and 5). However, 6 survivors (patients 1, 2, 4, 8, 21, and 25) maintained low titers over the study period (Tables 4, 5; Figure 2, panel C), but none of them became seronegative. Although most of the

survivors had a ≥ 4 -fold decline in IgG titer over time, all survivors maintained detectable antibody titers $\geq 1:400$ (Tables 4, 5; Figure 2, panel D). However, the overall response of IgA antibody was relatively weak, and 9 survivors (patients 1, 3, 4, 15, 18, 19, 21, 22, and 25) already had undetectable titer on day 200 (Tables 4, 5; Figure 2, panel E).

To further assess the physiologic contribution of the magnitude of the HI antibody titers, we transferred 40 μL convalescent-phase serum from individual patients to mice (online Technical Appendix Table 3). IgG titers in the serum samples of recipient mice correlated well with IgG, HI, and MN titers in the human serum samples, but we observed a better correlation for IgG titer in the human samples (Figure 3, panels A–D). Mouse IgG titers in the serum samples at the time of challenge correlated inversely with virus titers in the lung samples, confirming the importance of neutralizing antibodies assessed in laboratory analysis in virus clearance (Figure 3, panels E, F). These results also suggest that an IgG titer of $> 1:160$ was required to reduce virus titers by $0.5 \log_{10}$ in infected mice. Assuming that these numbers can be extrapolated to patients, transferring 40 μL of serum to a 13-g mouse is equivalent to transferring 210 mL of serum to a 70-kg patient (calculated per kilogram), thereby providing a potential guideline for its use in clinical settings.

The different types of antibody measures are significantly correlated with each other; we observed higher correlation between HI and NI and between NI and IgG at

Table 2. Underlying disease, complications, and treatment of influenza A(H7N9) virus survivors, China, 2017*

Patient no.	Underlying disease	Complications	Oxygen therapy	Mechanical ventilation	Days to antiviral treatment†	Oseltamivir	Glucocorticoid
1	HTN, DM	ARDS, RF	Yes	No	6	Yes	Yes
2	No	ARDS, RF	Yes	No	13	Yes	Yes
3	No	ARDS, RF	Yes	No	8	Yes	Yes
4	COPD, HTN	No	Yes	No	6	Yes	Yes
5	HTN	ARDS, RF	Yes	No	7	Yes	Yes
6	HTN, DM	ARDS, HI	Yes	No	14	Yes	No
7	No	ARDS	Yes	No	9	Yes	Yes
8	No	No	Yes	No	7	Yes	Yes
9	No	No	Yes	No	9	Yes	Yes
10	No	ARDS, RF, HI, RI	Yes	Yes	11	Yes	Yes
11	No	HI	Yes	No	7	Yes	Yes
12	No	No	Yes	No	8	Yes	No
13	No	No	Yes	No	8	Yes	Yes
14	No	No	Yes	No	6	Yes	Yes
15	No	HI	Yes	No	7	Yes	Yes
16	No	RF	Yes	No	13	Yes	No
17	No	ARDS	Yes	No	9	Yes	Yes
18	No	No	Yes	No	13	Yes	Yes
19	No	RF, HI	Yes	No	5	Yes	Yes
20	HTN	ARDS, RF, HI	Yes	Yes	11	Yes	Yes
21	HTN, DM, HL	ARDS, RF, HI	Yes	Yes	5	Yes	Yes
22	HTN	ARDS, RF, HI	Yes	No	7	Yes	Yes
23	HTN	No	Yes	No	6	Yes	NA
24	NA	NA	Yes	NA	1	Yes	NA
25	CHB	HI	Yes	No	9	Yes	Yes

*ARDS, acute respiratory distress syndrome; CB, chronic bronchitis; CHB, chronic hepatitis B infection; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HI, hepatic insufficiency; HL, hyperlipidemia; HTN, hypertension; NA, not available; RF, respiratory failure; RI, renal insufficiency. †After admission.

$R^2 > 0.5$ (online Technical Appendix Figure 1). We found no correlation between antibodies to the H7N9 virus and HI antibodies against seasonal H1N1 and H3N2 viruses ($p > 0.05$) (online Technical Appendix Figure 2), indicating that there is no heterologous boost of antibodies against H7 by H3 or H1 hemagglutinin. The antibody responses did not vary by patient age, sex, presence of underlying conditions, time in ICU, ventilation, or disease severity.

Discussion

In our study, antibodies to H7N9 virus waned over time, but most survivors maintained detectable antibody titers ≈ 1 year after infection. However, $>60\%$ of survivors had an HI titer $< 1:40$, which is potentially not seroprotective, ≈ 300 days after infection. Antibody responses were highly variable in survivors, and a few of them had weak antibody responses or had quickly waning antibody titers that were undetectable ≈ 1 year after infection despite their severity of infection. We also identified a threshold of IgG titer

that was crucial to virus clearance in the animal model and could be useful in clinical settings.

HI antibodies induced by natural infection with the 2009 pandemic H1N1 virus persist at constant high titer ($> 1:40$) for a minimum of 15 months (14). Additionally, the HI antibody against the H5N1 virus infection is reported to last even longer, at a stable titer ($\geq 1:40$) for nearly 5 years, although only a few survivors have been studied (15). In contrast, our study shows that only 36.4% of H7N9 survivors had HI titers $\geq 1:40$ at ≈ 1 year after infection, although most survivors had detectable HI antibody titers. On the other hand, we observed relatively high MN antibody titers persisting over time in survivors, and these levels were sufficient to predict protection, based on the protection extrapolated from seasonal influenza. If we assume that MN antibody is truly a better correlate of protection than HI antibody and a titer of $> 1:40$ is sufficient for protection, we could anticipate that most H7N9 survivors would remain protected against the H7N9 virus ≥ 1 year after infection.

Table 3. Proportion of influenza A(H7N9) virus survivors with titers at seroprotective levels at acute phase of infection and 3 follow-up points after infection, China, 2017*

Antibody	% Patients (95% CI)			
	Acute phase	Follow-up visit 1	Follow-up visit 2	Follow-up visit 3
HI	54.5 (32.2–75.6)	92.0 (74.0–99.0)	82.6 (61.2–95.0)	36.4 (17.2–59.3)
NI	50.0 (28.2–71.8)	96.0 (79.6–99.9)	91.3 (72.0–98.9)	63.6 (40.7–82.8)
MN	22.7 (7.8–45.4)	88.0 (68.8–97.5)	87.0 (66.4–97.2)	86.4 (65.1–97.1)
IgG	45.5 (24.4–67.8)	100 (86.3–100)	100 (85.2–100)	100 (84.6–100)
IgA	54.5 (32.2–75.6)	96.0 (79.6–99.9)	60.9 (38.5–80.3)	59.1 (36.4–79.3)

*Seroprotective levels for HI, NI, and MN titers, $\geq 1:40$; IgG $\geq 1:400$; or IgA $\geq 1:50$. HI, hemagglutination inhibition; MN, microneutralization; NI, neuraminidase inhibition.




Figure 2. GMTs (left) and individual titers (right) of antibodies to influenza A(H7N9) virus in serum samples collected from survivors, China, 2017: A) HI, B) NI, C) MN, D) IgG, and E) IgA. Red dashed line indicates threshold for seroprotective titer (HI, NI, and MN = 1:40) or limited detection titer (IgG = 1:400; IgA = 1:50). Error bars indicate 95% CIs. GMT, geometric mean titer; HI, hemagglutination inhibition; MN, microneutralization; NI, neuraminidase inhibition; P, patient.

Table 4. Antibody titers in survivors of influenza A(H7N9) during the acute phase and at 3 follow-up points, China, 2017*

Patient no.	HI/NI/MN/IgG/IgA titers			
	Acute phase	Follow-up visit 1	Follow-up visit 2	Follow-up visit 3
1	20/5/5/50/25	10/80/10/1600/50	10/40/10/800/25	10/20/10/800/25
2	20/5/5/50/50	10/10/20/1600/100	10/10/20/400/50	10/5/20/400/50
3	160/20/5/400/200	320/160/160/6400/50	160/160/320/6400/25	40/40/160/1600/25
4	40/320/20/400/25	40/320/20/3200/100	20/40/10/1600/25	5/10/10/800/25
5	5/5/5/100/25	640/5120/640/25600/1600	320/320/320/12800/800	40/80/320/3200/400
6	20/20/5/400/50	320/1280/160/3200/200	160/160/640/800/100	20/40/160/800/100
7	40/40/5/200/200	320/320/160/6400/800	NA	NA
8	40/5/5/50/25	320/320/40/1600/400	80/80/40/1600/200	20/20/40/800/100
9	5/5/5/100/25	80/1280/160/51200/400	40/40/160/6400/50	40/40/160/6400/50
10	1280/2560/160/12800/1600	160/2560/160/51200/800	80/320/320/12800/400	40/80/320/3200/200
11	40/10/5/100/100	80/80/80/6400/400	40/20/40/400/200	20/20/80/1600/100
12	40/40/5/800/50	80/5120/40/25600/200	NA	NA
13	20/10/5/400/100	160/1280/160/12800/400	80/320/320/3200/200	40/80/160/1600/200
14	5/5/5/50/25	160/160/160/3200/400	40/40/40/800/100	20/20/40/800/100
15	160/5120/160/3200/800	80/5120/160/3200/200	40/80/160/1600/25	20/80/160/1600/25
16	640/5120/160/12800/400	160/640/80/6400/800	80/320/160/3200/400	40/80/160/1600/400
17	20/160/5/100/25	160/320/80/12800/400	80/80/80/1600/400	40/40/80/1600/400
18	80/5/80/100/25	80/1280/80/1600/50	40/80/160/800/25	20/40/160/800/25
19	40/80/10/200/25	320/2560/640/25600/25	40/160/160/1600/25	20/40/160/1600/25
20	40/640/20/800/200	320/5120/640/3200/200	160/160/1280/6400/200	NA
21	NA	160/5120/40/6400/100	40/160/40/1600/25	20/80/40/1600/25
22	20/640/40/25/25	80/1280/40/3200/100	40/320/80/800/25	20/20/40/400/25
23	20/40/5/1600/200	320/5120/160/25600/800	80/160/160/3200/400	80/80/160/1600/400
24	NA	80/640/40/12800/100	40/160/160/3200/50	20/40/40/1600/50
25	NA	40/80/40/3200/50	20/20/40/1600/25	5/10/40/400/25

*HI, hemagglutination inhibition; MN, microneutralization; NA, not available; NI, neuraminidase inhibition.

It has been observed that antibody responses in infections with H5N1 or 2009 pandemic H1N1 virus in which patients had mild or no symptoms waned faster than those in patients with severe influenza disease and decreased below the threshold of positivity within 1 year (16,17). Of all reported H7N9 cases, <10% were

asymptomatic or mild (18–20), and our study included only 3 mildly symptomatic patients (patients 9, 18, and 25). These 3 patients maintained detectable NI, MN, and IgG antibodies, but patient 25 became seronegative for HI antibodies and IgA on or around day 305 after symptom onset. Meanwhile, several severely ill

Table 5. Change in antibody titers in survivors of influenza A(H7N9) at different follow-up points, China, 2017*

Patient no.	Change, -fold, HI/NI/MN/IgG/IgA	
	Follow-up visit 2 vs. follow-up visit 1	Follow-up visit 3 vs. follow-up visit 2
1	1/0.5/1/0.5/0.5	1/0.5/1/1/1
2	1/1/1/0.25/0.5	1/0.5/1/1/1
3	0.5/1/2/1/0.5	0.25/0.25/0.5/0.25/1
4	0.5/0.13/0.5/0.5/0.25	0.25/0.25/1/0.5/1
5	0.5/0.06/0.5/0.5/0.5	0.13/0.25/1/0.25/0.5
6	0.5/0.13/4/0.25/0.5	0.13/0.25/0.25/1/1
7	NA	NA
8	0.25/0.25/1/1/0.5	0.25/0.25/1/0.5/0.5
9	0.5/0.03/1/0.13/0.13	1/1/1/1/1
10	0.5/0.13/2/0.25/0.5	0.5/0.25/1/0.25/0.5
11	0.5/0.25/0.5/0.06/0.5	0.5/1/2/4/0.5
12	NA	NA
13	0.5/0.25/2/0.25/0.5	0.5/0.25/0.5/0.5/1
14	0.25/0.25/0.25/0.25/0.25	0.5/0.5/1/1/1
15	0.5/0.02/1/0.5/0.125	0.5/1/1/1/1
16	0.5/0.5/2/0.5/0.5	0.5/0.25/1/0.5/1
17	0.5/0.25/1/0.13/1	0.5/0.5/1/1/1
18	0.5/0.06/2/0.5/0.5	0.5/0.5/1/1/1
19	0.13/0.06/0.25/0.06/1	0.5/0.25/1/1/1
20	0.5/0.03/2/2/1	NA
21	0.25/0.03/1/0.25/0.25	0.5/0.5/1/1/1
22	0.5/0.25/2/0.25/0.25	0.5/0.06/0.5/0.5/1
23	0.25/0.03/1/0.13/0.5	1/0.5/1/0.5/1
24	0.5/0.25/4/0.25/0.5	0.5/0.25/0.25/0.5/1
25	0.5/0.25/1/0.5/0.5	0.25/0.5/1/0.25/1

*Change was calculated as ratio of titers. HI, hemagglutination inhibition; MN, microneutralization; NA, not available; NI, neuraminidase inhibition.




Figure 3. Testing of convalescent-phase serum transfer as potential protection against influenza A(H7N9) virus infection. Mice received 40 µL of patient serum intravenously 12 hours before H7N9 virus infection. A) IgG titers from mouse serum samples collected 1 h before infection. B–D) Relationships between IgG, HI, and MN titers in human serum and IgG titer in mouse recipients of transferred serum. E) Virus titers in homogenized mouse lungs at day 3 after infection (mean ± SE). F) Relationship between IgG titer in mouse serum samples and viral titers in mouse lung samples. HD, healthy donor; HI, hemagglutination inhibition; LOD, limit of detection; MN, microneutralization; S, serum; TCID₅₀, 50% tissue culture infectious dose.

patients had relatively weak antibody responses 100 days after symptom onset; in particular, patients 1, 2, and 4 either maintained low antibody titers over time or became seronegative at ≈1 year after symptom onset. Therefore, there was no clear association between disease severity and antibody response. Nevertheless, most patients in our study had severe symptoms, and so the findings may not be representative of mild cases or asymptomatic infections.

Previous seroepidemiological studies have identified the subclinical infections among both occupationally exposed workers and the general population, but the results varied (21–29). Similar to the problems with H5N1 infections in humans (30), the serologic threshold titer to recognize subclinical infections of the H7N9 virus is not yet established, which leads to difficulty in estimating

the seroprevalence of subclinical infections. A major problem in identifying such a serologic threshold for seropositivity is the insufficient immunogenicity of the H7 hemagglutinin (31–34). Our results show that HI, NI, IgG, and IgA antibodies declined substantially over time. In particular, for HI antibody, >60% of survivors had a titer <1:40, and 2 of them became negative at ≈1 year after infection. Given the low magnitude in HI antibody response, the true incidence of H7N9 infection is likely to be underestimated if a titer of >1:40 is used as the serologic threshold for the HI assay in seroepidemiological studies. In our study, the level of MN antibody titer was relatively stable over time and correlated well with other types of antibodies; therefore, the MN antibody could be a more useful indicator than HI for determining the incidence of infection.

Convalescent plasma therapy has been considered as a treatment option for new and emerging infectious diseases for which effective drugs and vaccines are not readily available. Although the anti-influenza A virus drug oseltamivir appeared to be useful for the treatment of H7N9 infection, the $\approx 40\%$ mortality rate still remains a challenge for clinical treatment, especially for severe cases who visit a hospital days past onset of their symptoms. Previous studies have shown that convalescent plasma treatment reduced the mortality rate of severe 2009 pandemic H1N1 infection (35) and benefited patients with severe H5N1 or H7N9 infections (36,37). Our results indicate that, despite substantially decreased HI antibody titers over time, most of the survivors still had a titer $>1:40 \approx 200$ days after infection, and high antibody titers are likely for other antibodies from survivors' serum. The experimental results from our model using mice suggest that transferring 210 mL of serum with HI titer $\geq 1:80$ to a 70-kg patient is a possible guideline for clinical treatment.

Our study had some limitations. First, our results need to be validated with larger numbers of survivors. We have thus far included 25 survivors, $\approx 3\%$ of all reported H7N9 survivors in China. The small sample size limited our ability to analyze the antibody response stratified by patient age, sex, underlying condition, or disease severity. Second, we could not collect blood samples more frequently from the patients, especially between acute phase and ≈ 100 days after infection, which could have provided a more complete picture about the dynamics of antibody responses. Finally, we did not study the virus-specific memory T- and B-cell response because of constraints in logistics. Whether there are correlations between cellular immune responses and antibody responses needs further investigation.

In conclusion, our findings contribute to the understanding of individual immune responses to H7N9 virus infection and of population-based immunity in regions where H7N9 virus outbreaks have occurred. Our study provides a useful serologic guideline for developing effective vaccines and therapies to counter H7N9 virus infections.

Acknowledgments

We thank all patients for their participation in the study and the staff of the local Centers for Disease Control and Prevention whose collaboration made this study possible.

This study was supported by the National Natural Science Foundation of China (81773494, 81402730, and 81621005); Beijing Scientific and Technology Nova Program (Z171100001117088); China Mega-Project on Infectious Disease Prevention (2017ZX10303401-006); Suzhou Key Technology on Major and Infectious Diseases Prevention and Control (GWZX201502); and Suzhou Medical Key Subject (SZXK201516).

About the Author

Dr. Ma is a scientist at Beijing Institute of Microbiology and Epidemiology, Beijing, China. His research interests focus on molecular epidemiology and seroepidemiology of zoonotic influenza virus and zoonotic transmission of influenza between species.

References

1. Food and Agriculture Organization of the United Nations. H7N9 situation update. 2017 [cited 2018 Jan 31]. http://www.fao.org/ag/againfo/programmes/en/empres/h7n9/situation_update.html
2. World Organisation for Animal Health. OIE situation report for avian influenza. 2017 [cited 2017 May 9]. http://www.oie.int/fileadmin/Home/eng/Animal_Health_in_the_World/docs/pdf/OIE_AI_situation_report/OIE_SituationReport_AI_6_8May2017.pdf
3. Shi J, Deng G, Kong H, Gu C, Ma S, Yin X, et al. H7N9 virulent mutants detected in chickens in China pose an increased threat to humans. *Cell Res.* 2017;27:1409–21. <http://dx.doi.org/10.1038/cr.2017.129>
4. Centers for Disease Control and Prevention. Influenza risk assessment tool (IRAT). 2017 [cited 2018 Jan 31]. <https://www.cdc.gov/flu/pandemic-resources/national-strategy/risk-assessment.htm>
5. Guo L, Zhang X, Ren L, Yu X, Chen L, Zhou H, et al. Human antibody responses to avian influenza A(H7N9) virus, 2013. *Emerg Infect Dis.* 2014;20:192–200. <http://dx.doi.org/10.3201/eid2002.131094>
6. Zhang A, Huang Y, Tian D, Lau EH, Wan Y, Liu X, et al. Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013. *Euro Surveill.* 2013;18:20657. <http://dx.doi.org/10.2807/1560-7917.ES2013.18.50.20657>
7. Huang R, Zhang L, Gu Q, Zhou YH, Hao Y, Zhang K, et al. Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9. *PLoS One.* 2014;9:e101788. <http://dx.doi.org/10.1371/journal.pone.0101788>
8. World Health Organization. Serological detection of avian influenza A(H7N9) virus infections by modified horse red blood cells haemagglutination-inhibition assay. 2013 [cited 2013 Dec 5]. http://www.who.int/influenza/gisrs_laboratory/cnic_serological_diagnosis_hai_a_h7n9_20131220.pdf
9. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. *J Clin Microbiol.* 1999;37:937–43.
10. Couzens L, Gao J, Westgeest K, Sandbulte M, Lugovtsev V, Fouchier R, et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. *J Virol Methods.* 2014;210:7–14. <http://dx.doi.org/10.1016/j.jviromet.2014.09.003>
11. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. *J Hyg (Lond).* 1972;70:767–77. <http://dx.doi.org/10.1017/S0022172400022610>
12. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. *Virus Res.* 2004;103:133–8. <http://dx.doi.org/10.1016/j.virusres.2004.02.025>
13. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. *BMC Med Res Methodol.* 2010;10:18. <http://dx.doi.org/10.1186/1471-2288-10-18>

14. Sridhar S, Begom S, Hoschler K, Bermingham A, Adamson W, Carman W, et al. Longevity and determinants of protective humoral immunity after pandemic influenza infection. *Am J Respir Crit Care Med*. 2015;191:325–32. <http://dx.doi.org/10.1164/rccm.201410-1798OC>
15. Kitphati R, Pooruk P, Lerdsamran H, Poosuwan S, Louisirothanakul S, Auewarakul P, et al. Kinetics and longevity of antibody response to influenza A H5N1 virus infection in humans. *Clin Vaccine Immunol*. 2009;16:978–81. <http://dx.doi.org/10.1128/CVI.00062-09>
16. Buchy P, Vong S, Chu S, Garcia JM, Hien TT, Hien VM, et al. Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. *PLoS One*. 2010;5:e10864. <http://dx.doi.org/10.1371/journal.pone.0010864>
17. Bonduelle O, Carrat F, Luyt CE, Lepout C, Mosnier A, Benhabiles N, et al. Characterization of pandemic influenza immune memory signature after vaccination or infection. *J Clin Invest*. 2014;124:3129–36. <http://dx.doi.org/10.1172/JCI74565>
18. Chen Z, Liu H, Lu J, Luo L, Li K, Liu Y, et al. Asymptomatic, mild, and severe influenza A(H7N9) virus infection in humans, Guangzhou, China. *Emerg Infect Dis*. 2014;20:1535–40. <http://dx.doi.org/10.3201/eid2009.140424>
19. Zeng X, Mai W, Shu B, Yi L, Lu J, Song T, et al. Mild influenza A/H7N9 infection among children in Guangdong Province. *Pediatr Infect Dis J*. 2015;34:104–7. <http://dx.doi.org/10.1097/INF.0000000000000492>
20. Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013–17: an epidemiological study of laboratory-confirmed case series. *Lancet Infect Dis*. 2017;17:822–32. [http://dx.doi.org/10.1016/S1473-3099\(17\)30323-7](http://dx.doi.org/10.1016/S1473-3099(17)30323-7)
21. Wang X, Fang S, Lu X, Xu C, Cowling BJ, Tang X, et al. Seroprevalence to avian influenza A(H7N9) virus among poultry workers and the general population in southern China: a longitudinal study. *Clin Infect Dis*. 2014;59:e76–83. <http://dx.doi.org/10.1093/cid/ciu399>
22. Yang P, Ma C, Cui S, Zhang D, Shi W, Pan Y, et al. Avian influenza A(H7N9) and (H5N1) infections among poultry and swine workers and the general population in Beijing, China, 2013–2015. *Sci Rep*. 2016;6:33877. <http://dx.doi.org/10.1038/srep33877>
23. Yang S, Chen Y, Cui D, Yao H, Lou J, Huo Z, et al. Avian-origin influenza A(H7N9) infection in influenza A(H7N9)-affected areas of China: a serological study. *J Infect Dis*. 2014;209:265–9. <http://dx.doi.org/10.1093/infdis/jit430>
24. Chen J, Ma J, White SK, Cao Z, Zhen Y, He S, et al. Live poultry market workers are susceptible to both avian and swine influenza viruses, Guangdong Province, China. *Vet Microbiol*. 2015;181:230–5. <http://dx.doi.org/10.1016/j.vetmic.2015.09.016>
25. Chen Z, Li K, Luo L, Lu E, Yuan J, Liu H, et al. Detection of avian influenza A(H7N9) virus from live poultry markets in Guangzhou, China: a surveillance report. *PLoS One*. 2014;9:e107266. <http://dx.doi.org/10.1371/journal.pone.0107266>
26. He F, Chen EF, Li FD, Wang XY, Wang XX, Lin JF. Human infection and environmental contamination with avian influenza A (H7N9) virus in Zhejiang Province, China: risk trend across the three waves of infection. *BMC Public Health*. 2015;15:931. <http://dx.doi.org/10.1186/s12889-015-2278-0>
27. Huang SY, Yang JR, Lin YJ, Yang CH, Cheng MC, Liu MT, et al. Serological comparison of antibodies to avian influenza viruses, subtypes H5N2, H6N1, H7N3, and H7N9 between poultry workers and non-poultry workers in Taiwan in 2012. *Epidemiol Infect*. 2015;143:2965–74. <http://dx.doi.org/10.1017/S0950268815000394>
28. Xiang N, Bai T, Kang K, Yuan H, Zhou S, Ren R, et al. Sero-epidemiologic study of influenza A(H7N9) infection among exposed populations, China 2013–2014. *Influenza Other Respi Viruses*. 2017;11:170–6. <http://dx.doi.org/10.1111/irv.12435>
29. Xu W, Lu L, Shen B, Li J, Xu J, Jiang S. Serological investigation of subclinical influenza A(H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province, China. *Clin Infect Dis*. 2013;57:919–21. <http://dx.doi.org/10.1093/cid/cit396>
30. Morens DM. Editorial commentary: pandemic H5N1: receding risk or coming catastrophe? *Clin Infect Dis*. 2013;56:1213–5. <http://dx.doi.org/10.1093/cid/cit051>
31. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. *Lancet*. 2004;363:587–93. [http://dx.doi.org/10.1016/S0140-6736\(04\)15589-X](http://dx.doi.org/10.1016/S0140-6736(04)15589-X)
32. Du Ry van Beest Holle M, Meijer A, Koopmans M, de Jager CM. Human-to-human transmission of avian influenza A/H7N7, the Netherlands, 2003. *Euro Surveill*. 2005;10:264–8. <http://dx.doi.org/10.2807/esm.10.12.00584-en>
33. Meijer A, Bosman A, van de Kamp EE, Wilbrink B, Du Ry van Beest Holle M, Koopmans M. Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test. *J Virol Methods*. 2006;132:113–20. <http://dx.doi.org/10.1016/j.jviromet.2005.10.001>
34. Couch RB, Decker WK, Utama B, Atmar RL, Niño D, Feng JQ, et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza A H5, H7 and H9 vaccines in humans. *PLoS One*. 2012;7:e50830. <http://dx.doi.org/10.1371/journal.pone.0050830>
35. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis*. 2011;52:447–56. <http://dx.doi.org/10.1093/cid/ciq106>
36. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. *N Engl J Med*. 2007;357:1450–1. <http://dx.doi.org/10.1056/NEJMc070359>
37. Wu XX, Gao HN, Wu HB, Peng XM, Ou HL, Li LJ. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. *Int J Infect Dis*. 2015;41:3–5. <http://dx.doi.org/10.1016/j.ijid.2015.10.009>

Address for correspondence: Wu-Chun Cao or Li-Qun Fang, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 20 Dongdajie, Beijing 100071, China; email: caowc@bmi.ac.cn or Fang_lq@163.com; Li-Ling Chen, Department of Infectious Diseases, Suzhou Municipal Center for Disease Control and Prevention, No. 72 Sanxiang Rd, Suzhou City, Jiangsu Province, China; email: liling_chen@163.com

Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017

Technical Appendix

Technical Appendix Table 1. Laboratory data for patients infected with influenza A(H7N9) virus on hospital admission, China, 2017*

Patient no.	C _t †			Virus isolation	HA lineage	ALT, U/L	AST, U/L	Creat, μmol/L	Leukocyte, ×10 ⁹ /L	CRP, mg/L	Temp, °C	Serum collection, d§
	Flu A	H7	N9									
1	32.54	29.04	30.35	Yes	YRD†	23	31	60.9	4.41	29.8	39	6, 161, 258, 369
2	27.56	32.64	30.89	No	NA	63	41	50.6	9.7	13	38	10, 126, 242, 349
3	29.37	28.03	29.32	No	NA	31	34	34.8	5.2	35.7	39.5	8, 126, 230, 332
4	30.58	32.96	30.79	No	NA	63	54	72.2	4.1	22.5	39.3	7, 99, 204, 307
5	30.04	29.97	30.72	Yes	YRD†	34.3	141.9	49	2.7	15.3	39	5, 99, 203, 300
6	28.12	29.35	28.58	No	NA	103	242	76	4.51	14.85	38.6	14, 99, 202, 307
7	28.62	28.25	28.54	No	NA	19	28	38.1	4.2	22.7	38.5	8, 96
8	30.12	29.57	29.51	Yes	YRD‡	113	118	70.8	4.12	197	40.5	7, 99, 203, 305
9	28.45	28.71	28.56	Yes	YRD‡	21	61	55	2.53	63.5	42	7, 96, 195, 298
10	30.56	31.63	31.95	No	NA	36	24	92	4.67	54.6	39.9	14, 89, 193, 301
11	28.52	29.13	29.65	Yes	YRD‡	15	16	50.6	3.59	31	39.9	7, 94, 194, 299
12	27.43	28.57	27.78	Yes	YRD‡	119.7	142.1	86	7.76	113.92	39.5	7, 84
13	30.5	30.28	32.1	Yes	YRD‡	219	53	64.5	4.1	67	39	8, 101, 189, 300
14	27.19	28.04	27.67	Yes	YRD‡	21	54	108.6	4.55	70	40.5	6, 85, 189, 298
15	28.55	29.01	28.69	Yes	YRD‡	45.7	56	33	4.92	15.42	40	19, 109, 214, 310
16	30.67	28.85	30.88	No	NA	33.5	80.5	57	4.92	14.68	39.5	17, 111, 215, 314

Patient no.	C _t †			Virus isolation	HA lineage	ALT, U/L	AST, U/L	Creat, μmol/L	Leukocyte, ×10 ⁹ /L	CRP, mg/L	Temp, °C	Serum collection, d§
	Flu A	H7	N9									
17	28	28.45	29.51	Yes	YRD‡	39	54	61.5	15.7	86.3	39	10, 106, 210, 307
18	28.18	28.36	29.05	No	NA	54	40	63.1	4.3	13	39.6	10, 119, 209, 318
19	30.22	29.75	30.52	No	NA	46.3	78.5	52	2.75	13.33	39	8, 82, 186, 292
20	29.35	29.24	29.02	No	NA	210	157	84	2.3	115	40	11, 79, 192
21	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	39	82, 186, 285
22	27.15	27.03	27.13	No	NA	32.3	89.3	92	2.49	15.92	39.6	35, 149, 261
23	27.67	28.87	28.73	No	NA	55	51	52	5.9	22.4	39.8	9, 51, 147, 254
24	NA	NA	NA	No	NA	NA	NA	NA	3.2	NA	40	6, 114, 211, 321
25	29.03	28.45	29.64	Yes	YRD‡	34	67	60.8	3.36	92.9	39	98, 195, 305

*ALT, alanine transaminase; AST, aspartate transaminase; Creat, creatinine; CRP, C-reactive protein; Ct, cycle threshold; leukocyte, leukocyte (leuckocyte) count; NA, not available; temp, body temperature;

YRD, Yangtze River Delta lineage.

†Ct values are based on virus levels detected in throat swabs of the patients.

‡Low pathogenicity avian influenza virus.

§After illness onset.

Technical Appendix Figure Table 2. Radiographic findings for patients infected with influenza A(H7N9) virus, China, 2017*


Patient no.	Radiographic findings
1	Inflammation in both lungs
2	Inflammation in both lungs
3	Exudative lesions in both lungs, inflammation in left lung
4	Infection in both lungs
5	Infection in left lung, left pleural effusion
6	Infection in both lungs, pleural thickening in both sides, left pleural effusion
7	Inflammation in both lungs
8	Infection, consolidation, and effusion in both lungs
9	Inflammation in both lungs
10	Inflammation in both lungs
11	Multi-patchy high-density shadow in both lungs
12	Inflammation in both lungs
13	Infection and consolidation in left lung
14	Infection and interstitial inflammation in right lower lung
15	Large high-density shadow and consolidation in two lungs
16	Infection in two lungs
17	Pneumonia in two lungs and particularly the right lung
18	Pneumonia in right lower lung
19	Ground-glass opacity in 2 lungs
20	Infection, emphysema, bullae in 2 lungs. Hydropneumothorax in right lung, effusion in left lung
21	NA
22	Consolidation in right lower lung. Hydropneumothorax with pulmonary atelectasis in right lung
23	Pneumonia in right lower lung
24	NA
25	Infection in right lower lung and right pleural effusion

*NA, not available.


Technical Appendix Table 3. Antibody titers in human and mouse serum, and virus titer in mice lungs

Serum no.	IgG antibody of human serum	HAI antibody of human serum	MN antibody of human serum	IgG antibody titer in mouse serum	TCID ₅₀ in mice lungs
S1	200	5	5	5	2.58
S2	400	10	5	20	2.46
S3	1600	20	10	20	2.22
S4	800	20	20	40	2.22
S5	1600	20	20	20	2.22
S6	3200	40	40	160	2.28
S7	6400	80	80	160	2.04
S8	12800	160	160	320	2.06
S9	25600	160	640	320	2.04
S10	12800	320	320	320	2.03
S11	12800	640	1280	320	2.00
S12	12800	1280	2560	320	1.83
PBS	—	—	—	5	2.67
HD	100	5	5	5	2.63

*HD, healthy donor; HAI, hemagglutination inhibition; MN, microneutralization; S, serum.



Technical Appendix Figure 1. Correlation analysis among titers of hemagglutination inhibition (HI), neuraminidase inhibition (NI), microneutralization (MN), IgG, and IgA antibodies against the influenza A(H7N9) virus in survivors.



Technical Appendix Figure 2. Hemagglutination inhibition (HI) antibodies to human seasonal influenza H3 and H1 viruses in survivors and their correlation with HI antibody to the H7N9 virus. A) HI geometric mean titer (GMT) to H1 and H3 subtypes in influenza survivors. B) Correlation between HI antibody to the H7N9 virus and H3 (B) subtype. C) Correlation between HI antibody to the H7N9 virus and H1 subtype.